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Abstract
Targeted therapies including tumour necrosis factor α (TNFα) inhibitors have trans‐
formed the management of a number of autoimmune conditions over the past 20 years.
One autoimmune rheumatological condition with significant potential for the develop‐
ment of targeted therapies is systemic sclerosis (SSc). In this chapter, we use SSc as an
example  of  how  research  into  the  pathogenic  processes  underlying  autoimmune
conditions can be translated into novel targeted therapies. We review the evidence base
for a range of targeted therapies for SSc identified from a systematic literature search,
before highlighting a number of studies currently underway.
Keywords: systemic sclerosis, scleroderma, targeted therapies, biological therapy, bio‐
logic, rheumatology, rheumatoid arthritis, autoimmune
1. Introduction
1.1. Targeted therapies in autoimmune conditions
Targeted therapies have revolutionised the management of many autoimmune rheumatological
conditions over the last 20 years. Ground‐breaking research in the early 1990s identified tumour
necrosis factor alpha (TNFα) as a key inflammatory mediator of rheumatoid arthritis [1–6]. This
research enabled the development of targeted TNFα inhibitors, such as adalimumab, infliximab
and etanercept. Although costly, these therapies have greatly improved the outlook for patients
with severe, active rheumatoid arthritis [7, 8].
As we improve our understanding of the pathogenic processes underlying rheumatoid ar‐
thritis, the number of potential targets for novel therapies increases. Several additional tar‐
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geted therapies are now licensed for the treatment of patients with severe rheumatoid
arthritis who have failed to respond adequately to, or been unable to tolerate, conventional
immunosuppressive therapies. Examples include: rituximab, a B‐lymphocyte‐depleting
monoclonal antibody targeting the CD20 antigen; abatacept, a fusion protein that abrogates
the co‐stimulatory signals required for the activation of T‐lymphocytes; tocilizumab, an in‐
terleukin (IL)‐6 receptor antagonist; and anakinra, an IL‐1 receptor antagonist [8–13].
The process of translating research on autoimmune pathogenesis into targeted therapies has
not been limited to rheumatoid arthritis, however. TNFα inhibitors have also been shown to
be highly effective in psoriasis and psoriatic arthritis, as well as ankylosing spondylitis, juvenile
idiopathic arthritis and inflammatory bowel disease [14–17]. Targeted therapies with novel
mechanisms of action have also been developed for a number of autoimmune rheumatological
conditions. Ustekinumab, a humanised monoclonal antibody directed against IL‐12/23, is
licensed as a treatment for both psoriasis and psoriatic arthritis [18]. Secukinumab, an IL‐17
inhibitor, has also been shown to be efficacious in the treatment of both psoriasis and psoriatic
arthritis [19, 20]. In the case of autoantibody‐positive systemic lupus erythematosus, belimu‐
mab, an inhibitor of B‐lymphocyte stimulator, has recently been licensed as an adjunctive
therapy [21].
An autoimmune rheumatological condition with a great need for targeted therapies is systemic
sclerosis (SSc). In this chapter, we use SSc as an example of how research into pathogenic
processes can be translated into novel therapeutic targets for autoimmune conditions.
1.2. Background to systemic sclerosis
SSc is a multi‐system autoimmune condition that typically arises between the ages of 30 and
50 years, with women affected approximately four times more frequently than men. The
aetiology of SSc remains to be elucidated and is likely to involve complex interactions between
environmental factors in genetically predisposed individuals. Multiple cell types, cytokines
and signalling pathways contribute to three sustained and interdependent pathogenic
processes that form the hallmark of SSc: excessive extracellular matrix production and
deposition by fibroblasts, inflammation and vascular abnormalities [22]. These processes
culminate in multi‐organ fibrosis, in addition to vascular manifestations, such as pulmonary
arterial hypertension (PAH), Raynaud's phenomenon (RP) and renal crises.
Fibrotic thickening and hardening of the skin, termed sclerodactyly, can lead to profound
physical and psychological morbidity. Gastrointestinal tract fibrosis can produce a range of
complications depending on the portions of the tract involved, including oesophageal reflux
and strictures, gastroparesis, small bowel bacterial overgrowth and constipation. Pulmonary
involvement represents the leading cause of death in patients with SSc, with interstitial lung
disease (ILD) and PAH typically presenting with progressive breathlessness on exertion. Two
additional presenting features of SSc, often occurring in the early stages of the disease, are
digital swelling and RP. In the case of the latter, vasospastic changes produce a characteristic
whitening of the distal portions of the fingers and toes that progresses to a blue discolouration
(representing cyanosis), before flushing red as blood flow returns. In SSc, RP can be severe
enough to result in digital ulceration and necrosis.
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SSc can be subdivided into two main forms depending on the extent of skin involvement. In
limited cutaneous systemic sclerosis (lcSSc), fibrosis occurs in the skin of the face and in the
skin distal to the elbows and knees. A term often used interchangeably with lcSSc is CREST
syndrome, an acronym representing five cardinal signs and symptoms that arise in a subset
of patients with lcSSc: calcinosis, RP, oesophageal dysmotility, sclerodactyly and telangiectasia.
Diffuse cutaneous systemic sclerosis (dcSSc) is characterised by more extensive skin involve‐
ment than lcSSc, such that the proximal arms, legs and trunk are often affected. The onset and
progression of skin changes are usually more rapid in dcSSc than in lcSSc, with multi‐organ
fibrosis typically occurring to a greater extent.
1.3. Management of systemic sclerosis
The mainstay of management of SSc involves close monitoring for systemic complications,
with treatment as they arise [22]. A multidisciplinary approach is essential, with involvement
of clinicians from a range of specialties, as well as physiotherapists, occupational therapists
and psychologists [23, 24].
For skin involvement, topical steroids and emollients can help to ameliorate any associated
pruritus and xerosis. Camouflage products are also effective in minimising the cosmetic effects
of hypopigmented and hyperpigmented areas of skin, as well as telangiectasia. Regular
physiotherapy, along with orthoses, decreases the risk of sclerodactyly‐induced contractures.
However, surgery may ultimately be required in the case of established contractures.
Acid‐suppressant therapies, such as proton‐pump inhibitors, and pro‐motility agents, such as
metoclopramide, are frequently used to treat SSc‐associated gastro‐oesophageal reflux and
gastroparesis, respectively. Should strictures of the oesophagus arise, endoscopic dilatation
can be employed. With more distal gastrointestinal tract involvement, dietetic input can help
to counter the malabsorptive effects of small bowel dysmotility and bacterial overgrowth. The
latter may also necessitate cyclical treatment with antibiotics. Laxative therapy, pro‐motility
agents and ensuring an adequate intake of fibre can minimise the constipation that arises from
colonic dysmotility.
A potentially fatal complication of SSc, requiring emergent treatment, is a scleroderma renal
crisis. This typically presents with acute‐onset hypertension and renal impairment, and can
rapidly progress to renal failure without prompt recognition and treatment. Angiotensin‐
converting enzyme inhibitors are the cornerstone of management of such crises. Their use has
greatly improved the prognosis associated with scleroderma renal crises, such that this
complication is no longer the leading cause of death in patients with systemic sclerosis.
Significant progress has also been made in the management of SSc‐associated RP. Treatment
options available include calcium‐channel blockers, such as nifedipine, phosphodiesterase
type‐5 inhibitors, such as sildenafil, and angiotensin II receptor antagonists, such as losartan.
In cases of digital ulceration and impending digital necrosis, inpatient admission may be
required for intravenous prostanoid therapy. Phosphodiesterase type‐5 inhibitors and
prostaglandin infusions are also effective treatments for SSc‐associated PAH. Additionally,
bosentan, an endothelin‐receptor antagonist, has been shown to be efficacious in the manage‐
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ment of both SSc‐associated PAH and digital ulcers. Bosentan is a rare example of a targeted
therapy licensed for use in SSc and is covered in greater detail later in this chapter.
Multiple immunosuppressive medications have been trialled in SSc. The evidence base is weak,
however, and clinical trials of such medications are limited by the rarity and heterogeneity of
SSc, and the variability in the natural progression of the disease. As is true of other autoimmune
rheumatological conditions, there is a growing trend for early, aggressive treatment of SSc with
immunosuppressive regimens [23, 24]. This is particularly true of dcSSc, where early immu‐
nosuppression has the potential to stem the progression of the disease. Typical first‐line
treatment options for SSc‐associated ILD include intravenous cyclophosphamide (as induction
therapy) followed by an oral agent such as mycophenolate mofetil (as maintenance therapy).
In cases of extensive SSc‐associated skin fibrosis, treatment options include mycophenolate
mofetil and methotrexate, as well as azathioprine, cyclophosphamide and corticosteroid
therapy [24].
Relative to other autoimmune conditions, such as rheumatoid arthritis, the efficacy of immu‐
nosuppressive regimens in the treatment of SSc is modest [25]. Broad‐spectrum immunosup‐
pression also carries with it the risk of infection and bone marrow suppression, as well as
agent‐specific side effects, such as bladder toxicity with cyclophosphamide therapy. As such,
there is a concerted effort to find novel treatment options for SSc. One example is autologous
haematopoietic stem cell transplantation, which has a growing evidence base in SSc. In selected
patients with early dcSSc and poor prognostic features, stem cell transplantation has been
shown to improve long‐term event‐free and overall survival rates, relative to IV cyclophos‐
phamide [26, 27]. These benefits have to be weighed against early transplant‐related mortality
rates of 10%, however. As such, the use of stem cell transplantation is restricted to those patients
with early dcSSc who are yet to develop severe organ involvement. Another example of an
emerging therapy is intravenous immunoglobulin (IVIg), with a number of pilot studies
reporting improvements in skin fibrosis scores, gastrointestinal manifestations and joint‐
related symptoms [28–31].
Despite some progress in the management of SSc, there remains a great need for therapies that
target the specific pathogenic processes underlying the disease, namely fibrosis, inflammation
and vascular damage. The development of efficacious targeted therapies has the potential to
transform the management of this disabling condition, just as TNFα inhibitors have done in
rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. In this chapter, we use SSc
as an example of how research into pathogenic processes can be translated into novel thera‐
peutic targets for autoimmune conditions.
2. Body
We performed a systematic search of the PubMed and Cochrane medical literature databases
to identify all clinical studies involving therapeutic interventions in patients with systemic
sclerosis during the last 10 years (covering the period of July 2006–June 2016). Using a broad
search strategy, we identified 2381 articles. We reviewed the abstracts of these articles and
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selected those studies involving therapies with targeted mechanisms of action, that is,
treatments targeting specific molecular and/or cellular pathways known to be involved in the
pathogenesis of SSc. Studies were excluded if they were not written in English, if they did not
involve human subjects or if they had less than three study subjects. In total, 69 studies were
identified and the details are shown in Table 1. The majority of the therapies identified can be
grouped into three broad categories, corresponding to which of the central pathogenic
processes they target: fibrosis, inflammation or vascular abnormalities. It is important to note,
however, that these processes are very much interdependent and, as such, targeting one
pathway is likely to impact on one or more of the other processes [32].
Study
treatment 
Ref. Treatment
dosage
Disease
aspect
studied
Study type Duration of
study
Number
drug/
control
p‐value
(measure)
Fibrosis
TGF‐β pathway inhibitors
CAT‐192 [35] Various dcSSc RCT 6 months 32/11 >0.05 (mRSS)
Fresolimumab [37] Various dcSSc Prospective 24 weeks 15/0 <0.001 (mRSS)
Pirfenidone [42] 2403 mg daily SSc‐ILD Prospective 16 weeks 63/0 >0.05 (PFTs,
mRSS)
Pirfenidone [43] 1200/1800 mg
daily
SSc‐ILD Case series Various 5/0 N/A
Tyrosine kinase inhibitors
Imatinib mesylate [45] 400 mg daily dcSSc RCT 6 months 9/1 >0.05 (mRSS)
Imatinib mesylate [46] 600 mg daily SSc‐ILD Prospective 12 months 20/0 >0.05 (PFTs),
<0.001 (mRSS)
Imatinib mesylate [47] 400 mg daily dcSSc Prospective 12 months 30/0 <0.001 (mRSS),
0.008 (FVC)
Imatinib mesylate [48] 400 mg daily dcSSc Prospective 36 months 17/0 0.002 (mRSS)
Imatinib mesylate [49] 200 mg daily SSc‐ILD Prospective 12 months 30/0 N/A
Imatinib mesylate [126] 400 mg daily SSc/
morphoea
RCT 12 months 15/13 >0.05 (mRSS)
Imatinib mesylate [127] 200 mg daily SSc Case series 23 months 6/0 N/A
Imatinib mesylate [128] 100 mg daily SSc skin Case series 6 months 3/0 N/A
Imatinib mesylate
+ CYC
[129] 200 mg daily SSc‐ILD Case series 12 months 5/0 N/A
Nilotinib [50] 800 mg daily dcSSc Prospective 12 months 10/0 0.02 (mRSS)
Other agents
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Study
treatment 
Ref. Treatment
dosage
Disease
aspect
studied
Study type Duration of
study
Number
drug/
control
p‐value
(measure)
Oral type I
collagen
[51] 500 µg daily dcSSc RCT 15 months 83/85 >0.05 (mRSS)
Relaxin [53] 10/25 µg/kg daily dcSSc RCT 24 weeks 137/94 >0.05 (mRSS)
Inflammation
TNFα inhibitors
TNFα inhibitors [54] Various SSc Retrospective Various 65/0 N/A
Etanercept [60] 50 mg/week SSc‐m'skel Retrospective Various 18/0 >0.05 (HAQ,
mRSS)
Infliximab [61] 5 mg/kg ×5 dcSSc Prospective 26 weeks 16/0 >0.05 (mRSS,
HAQ)
Selective co‐stimulation modulators
Abatacept [67] 500/1000 mg ×7 dcSSc RCT 24 weeks 7/3 0.06 (mRSS)
Abatacept +
tocilizumab
[68] Various SSc‐m'skel Observational 11 months 27/0 <0.001 (DAS28)
Abatacept [130] 500/750 mg/4
weeks
dcSSc Case series Various 4/0 N/A
IL‐2α inhibitors
Basiliximab [72] 20 mg ×6 dcSSc Prospective 68 weeks 10/0 0.015 (mRSS),
>0.05 (FVC/DLco)
IL‐6 inhibitors
Tocilizumab +
abatacept
[68] Various SSc‐m'skel Observational 5 months 27/0 0.001 (DAS28)
Tocilizumab [77] 8 mg/kg/4 weeks SSc Case series Various 3/0 N/A
Tocilizumab [78] 162 mg/week SSc RCT 48 weeks 43/44 0.09 (mRSS)
B‐cell depletion
Rituximab [81] Various SSc Case‐control Various 63/25 0.03 (mRSS), 0.02
(FVC)
Rituximab [82] 1000 mg ×2 dcSSc Prospective 6 months 15/0 >0.05 (mRSS)
Rituximab [83] (500 mg ×2)/3
months
SSc‐ILD Case series 12 months 5/0 <0.001 (mRSS,
DLco), <0.004
(FVC)
Rituximab [84] 1000 mg ×2 dcSSc Prospective 24 weeks 8/0 <0.001 (mRSS)
Rituximab [85] 1000 mg ×2 SSc Prospective 36 months 9/0 0.001 (mRSS)
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Study
treatment 
Ref. Treatment
dosage
Disease
aspect
studied
Study type Duration of
study
Number
drug/
control
p‐value
(measure)
Rituximab [86] (375 mg/m2 ×4)/6
months
dcSSc Prospective 12 months 25/0 0.001 (FVC), 0.008
(DLco), 0.0001
(mRSS)
Rituximab [87] (375 mg/m2 ×4)/24
weeks
SSc RCT 12 months 8/6 0.002 (FVC),
<0.001 (mRSS)
Rituximab [88] (375 mg/m2 ×4)/6
months
SSc‐ILD Prospective 24 months 8/0 <0.0001 (FVC,
mRSS), <0.001
(DLco)
Rituximab [89] (1000 mg ×2)/6
months
dcSSc Prospective 24 months 8/0 <0.0001 (mRSS,
DAS)
Rituximab [90] Various SSc Prospective 7 years 30/0 0.018 (FVC), 0.012
(DLco), <0.001
(mRSS)
MEDI‐551 [91] Various SSc RCT 85 days 24/4 N/A
Type I IFN receptor antagonists
MEDI‐546 [92] Various SSc Prospective 12 weeks 34/0 N/A
Vascular
Endothelin receptor antagonists
Bosentan [97] 250 mg daily SSc‐RP/skin Retrospective 48 weeks 14/0 <0.05 (RP attacks),
<0.01 (mRSS)
Bosentan [99] 250 mg daily SSc‐PAH Prospective Various 49/0 0.014 (NYHA
class), >0.05
(6MWD)
Bosentan [100] 250 mg daily SSc‐DU RCT 24 weeks 98/90 0.04 (DU
episodes), >0.05
(DU healing)
Bosentan [101] 250 mg daily SSc‐DU Retrospective 24 months 67/0 N/A
Bosentan [102] 250 mg daily SSc‐DU Prospective 36 months 26/0 <0.001 (DU
number)
Bosentan [103] 62.5–125 mg daily SSc‐DU Case series Various 6/0 N/A
Bosentan [108] 250 mg daily SSc‐RP Prospective 16 weeks 15/0 <0.05 (RP attacks)
Bosentan [112] 250 mg daily SSc‐ILD RCT 12 months 77/86 >0.05 (6MWD,
PFTs)
Bosentan [113] 250 mg daily SSc‐ILD Prospective 24 months 9/0 N/A
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Study
treatment 
Ref. Treatment
dosage
Disease
aspect
studied
Study type Duration of
study
Number
drug/
control
p‐value
(measure)
Bosentan [114] 250 mg daily SSc‐skin Prospective 24 weeks 10/0 <0.001 (mRSS, DU
healing)
Bosentan +
iloprost
[131] 250 mg daily SSc‐vascular Observational 3 years 13/13 <0.01 (PBP)
Bosentan [132] 250 mg daily SSc‐DU/PAH Prospective Various 54/0 <0.001 (DU
episodes)
Bosentan [133] 250 mg daily SSc‐NDU Case series Various 5/0 N/A
Bosentan [134] 250 mg daily SSc‐vascular Prospective 16 weeks 30/30 N/A
Bosentan [135] 250 mg daily SSc‐RP RCT 24 weeks 9/8 >0.05 (RP attacks),
0.01 (HAQ)
Bosentan [136] 250 mg daily CTD‐PAH/
skin
Observational 24 months 15/0 <0.01 (6MWD,
mRSS),
Bosentan [137] 250 mg daily CTD‐PAH Prospective 48 weeks 53/0 N/A
Bosentan [138] 250 mg daily SSc‐DU Prospective Various 15/0 <0.05 (DU
number)
Bosentan [139] 125 mg daily SSc‐vascular Prospective 4 weeks 12/12 <0.001 (FMD)
Bosentan [140] 250 mg daily SSc‐vascular Prospective 6 months 18/0 >0.05 (multiple
measures)
Bosentan [141] 250 mg daily SSc‐RP Observational 16 weeks 3/0 N/A
Bosentan [142] 250 mg daily SSc‐PAH Prospective 6 months 8/0 0.01 (6MWD)
Bosentan [143] 250 mg daily SSc‐DU Prospective 12 weeks 52/51 <0.05 (blood flow)
Bosentan [144] 250–500 mg daily CTD‐PAH RCT 12‐16 weeks 44/22 >0.05 (6MWD)
Ambrisentan +
tadalafil
[105] 10 + 40 mg SSc‐PAH Prospective 36 weeks 24/0 <0.05 (RV mass),
<0.0001 (PVR)
Ambrisentan [106] 5–10 mg daily SSc‐PAH Prospective 24 weeks 12/0 0.004 (PVR), 0.003
(6MWD)
Ambrisentan [107] 5 mg daily SSc‐DU/RP Prospective 6 months 6/0 <0.03 (DU
healing), 0.01 (RP
attacks)
Ambrisentan [145] Up to 10 mg/day SSc‐DU Prospective 24 weeks 20/0 0.004 (DU
number)/0.0001
(DU diameter)
Ambrisentan [146] 10 mg daily SSc‐vascular RCT 12 weeks 15/5 >0.05 (blood flow),
0.005 (HAQ)
Immunopathogenesis and Immune-based Therapy for Selected Autoimmune Disorders104
Study
treatment 
Ref. Treatment
dosage
Disease
aspect
studied
Study type Duration of
study
Number
drug/
control
p‐value
(measure)
Macitentan [115] 3/10 mg daily SSc‐DU RCT (x2) 16 weeks 192/97
176/89 
>0.05 (DU
formation)
Other agents
Fasudil [116] 40/80 mg SSc‐RP RCT crossoverVarious 17/0 >0.05 (blood flow
recovery)
ORM‐12741 [117] 30/100 mg SSc‐RP RCT crossoverVarious 12/0 >0.05 (blood flow
recovery)
Ref. = study reference, Number drug/control = number of subjects in the treatment and control arms of the study, and p‐
value (measure) = statistical significance of the outcome measure defined in brackets.
TNFα, tumour necrosis factor alpha; CYC, cyclophosphamide; SSc, systemic sclerosis; dcSSc, diffuse cutaneous
systemic sclerosis; CTD, connective tissue disorder; SSc‐ILD, systemic sclerosis‐associated interstitial lung disease; SSc‐
m'skel, systemic sclerosis‐associated musculoskeletal manifestations; SSc‐skin, systemic sclerosis‐associated skin
manifestations; SSc‐vascular, systemic sclerosis‐associated vascular manifestations; SSc‐DU, systemic sclerosis‐
associated digital ulcers; SSc‐PAH, systemic sclerosis‐associated pulmonary arterial hypertension; SSc‐NDU, systemic
sclerosis‐associated nondigital ulceration; SSc‐RP, systemic sclerosis‐associated Raynaud's phenomenon; RCT,
randomised‐controlled trial; mRSS, modified Rodman skin score; PFTs, pulmonary function tests; FVC, forced vital
capacity; HAQ, health assessment questionnaire; DAS28, disease activity score at 28 joints; DLco, diffusing capacity of
carbon monoxide; PBP, peripheral blood perfusion; DU, digital ulcer; RP, Raynaud's phenomenon; 6MWD 6‐min
walking distance; NYHA class, New York Heart Association Functional Classification of Heart Failure; FMD, flow‐
mediated dilatation; RV mass, right ventricular mass; PVR, pulmonary vascular resistance; N/A, not applicable/
specified.
Table 1. Clinical studies of targeted therapies in systemic sclerosis published during the last 10 years.
2.1. Fibrosis
2.1.1. TGF‐β pathway inhibitors
Central to the fibroblast‐mediated overproduction of extracellular matrix and perturbed tissue
repair in SSc are a number of pro‐fibrotic growth factors, the most notable of which is trans‐
forming growth factor‐β (TGF‐β). The TGF‐β pathway has been strongly implicated in the
pathogenesis of systemic sclerosis in numerous in vitro and in vivo studies. One such example
is the reduction in fibrosis seen in mouse models following the abrogation of TGF‐β signalling
[33, 34]. As such, the TGF‐β pathway has been the focus of a number of studies in the search
for targeted therapies for SSc, with several different approaches tested.
A logical approach is to target the growth factors themselves using neutralising antibodies.
One of the first anti‐TGF‐β antibodies to be trialled in SSc was CAT‐192, a recombinant human
antibody against the TGF‐β1 isoform. In Denton et al.'s pioneering study, CAT‐192 was
administered at different doses to a cohort of patients with early dcSSc using a randomised,
double‐blind, placebo‐controlled study design [35]. Of the 45 patients enrolled into the study,
31 patients completed the trial. Four patients who received CAT‐192 died during the study,
although these deaths were thought to be a consequence of the underlying disease as opposed
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to a direct result of treatment with CAT‐192. Skin sclerosis scores, as determined by the
modified Rodman skin score (mRSS), did not demonstrate any significant treatment effect for
CAT‐192, with a global improvement in mRSS occurring independently of CAT‐192 treatment.
Similarly, no significant differences were noted in pulmonary function or functional status, as
determined by the Scleroderma Health Assessment Questionnaire (HAQ). Furthermore, an
excess of adverse events and severe adverse events was noted in the CAT‐192 treatment group,
although the majority were thought not to be related to treatment.
As noted by Denton et al., the lack of efficacy shown by CAT‐192 could possibly be explained
by its relatively weak affinity for only one isoform of TGF‐β ligand. They suggest that abro‐
gation of all active isoforms of the TGF‐β ligand might induce a greater anti‐fibrotic effect, as
demonstrated in animal models [35]. Importantly, however, the desire to abrogate pro‐fibrotic
pathways must be balanced against the loss of their normal physiological functions, including
potential tumour‐suppressant roles [36].
Fresolimumab is a neutralising antibody targeting all three isoforms of TGF‐β. Rice et al.
conducted an open‐label pilot study of fresolimumab in 15 patients with early dcSSc, employ‐
ing two different dosing schedules [37]. mRSS values were shown to improve significantly
by 3 weeks (p = 0.0002), with the changes remaining significant at 17 weeks (p = 0.0024). The
clinical improvements in skin thickness paralleled a decrease in the expression of TGF‐β‐
related biomarkers in skin biopsies following fresolimumab treatment. Interestingly, by 24
weeks, the subjects’ skin scores had begun to deteriorate, along with re‐expression of the TGF‐
β‐mediated biomarkers, suggesting progression of the underlying skin disease. This led the
authors to question whether a longer course of treatment, or repeated treatments, might help
to sustain the treatment response. This must be balanced against adverse treatment effects,
however. Anaemia was the most commonly reported adverse event in the study, with 67% of
subjects experiencing a decrease in haemoglobin levels of >10% from baseline. Bleeding from
sites including the gastrointestinal tract, gums, eyes and nose was also reported in a number
of patients.
Another anti‐fibrotic agent thought to act, at least in part, by suppressing TGF‐β signalling is
pirfenidone. Pirfenidone is also thought to possess anti‐inflammatory properties, with action
against TNFα demonstrated in several studies [38, 39]. This dual anti‐fibrotic and anti‐
inflammatory action makes pirfenidone an attractive candidate for use in SSc. Indeed,
pirfenidone has been extensively studied in idiopathic pulmonary fibrosis, with several large
phase III studies demonstrating improvements in progression‐free survival [40, 41].
Khanna et al. recently studied pirfenidone in a 16‐week, open‐label study of 63 patients with
SSc‐associated interstitial lung disease (SSc‐ILD) [42]. The primary aim of the study was to test
pirfenidone's safety and tolerability in such patients. The vast majority of subjects did indeed
experience adverse events during the course of the study, although most were mild or moderate
in severity, with a similar adverse event profile to previous studies of pirfenidone in idiopathic
pulmonary fibrosis. Median changes (from baseline) in the percentage of predicted forced vital
capacity (FVC) and diffusing capacity of carbon monoxide (DLco) were non‐significant, at
‐0.5% and +1.5%, respectively. Clinically insignificant changes in skin scores were also noted.
Of note, the authors state clearly that this study was inadequately powered to assess efficacy.
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Further studies are required before conclusions can be drawn on pirfenidone's efficacy in SSc.
A case series of five patients with SSc‐ILD treated with pirfenidone has provided hope of a
potential benefit [43]. Vital capacity (as a percentage of predicted) was shown to improve by
12.2–28.9% in four patients following pirfenidone therapy, depending on the duration of
follow‐up. In the case of the fifth patient, vital capacity improved by a more modest 3.8% after
pirfenidone therapy, albeit after only 3 months of follow‐up. Furthermore, the authors noted
that dyspnoea was attenuated in three patients, along with a reduction in ground‐glass
shadowing seen on the chest imaging of two patients. In another study of 12 patients, the
potential benefits of topical pirfenidone in patients with localised scleroderma (morphoea)
were demonstrated, with significant improvements seen in skin scores (p = 0.002) and histo‐
pathological markers (p = 0.032) at 6 months [44].
2.1.2. Tyrosine kinase inhibitors
Another approach is to target the downstream pathways induced by pro‐fibrotic molecules
such as TGF‐β and platelet‐derived growth factor (PDGF). The downstream pathways induced
by these molecules require tyrosine kinase signalling [45]. Tyrosine kinase inhibitors are
therefore strong candidates for use as anti‐fibrotic agents in SSc. This is facilitated by the fact
that several of these agents are already widely used in other conditions, such as in chronic
myeloid leukaemia.
Pope et al. tested imatinib mesylate, an inhibitor of the BCR‐ABL, c‐kit and PDGF tyrosine
kinase receptors, in a randomised, double‐blind, placebo‐controlled study of patients with
active dcSSc over a 6‐month period [45]. Outcomes measured included changes in skin scores,
global assessments of patients’ well‐being and safety outcomes. Despite a plan to enrol 20
patients into the study, enrolment was cut short after 10 patients in view of the high observed
number of adverse events. Side effects noted included diarrhoea, nausea, oedema and alopecia,
with two patients requiring hospital admission. The tolerability remained poor despite a dose
reduction from 200 mg twice daily to 200 mg once daily. Of the efficacy outcome measures
assessed, no significant treatment effect was observed in skin scores or global assessment
measures, although conclusions were limited by the small number of subjects and short study
duration.
Focusing on SSC‐associated lung fibrosis, Khanna et al. performed a 1‐year, open‐label study
of imatinib in 20 SSc patients with active ILD [46]. Doses of up to 600 mg per day were used,
with a mean dosage of 445 mg per day. In keeping with the outcome of Pope et al.'s study, 25%
of subjects discontinued this study as a result of adverse events, with a similar profile of side
effects noted. A modest, non‐significant improvement in FVC was observed in patients
receiving imatinib, coupled with a significant improvement in skin scores (p < 0.001). Further
corroborating the results of this study, Spiera et al. demonstrated a significant improvement
in skin scores (p < 0.001) and FVC (p = 0.008) in their open‐label, 1‐year study of imatinib 400
mg daily in 30 patients with dcSSc [47]. The improvements in skin scores seen in this study
paralleled significant decreases in skin thickness as evident on skin biopsy (p < 0.01). Again, a
large number of adverse events were noted in this study, with 171 adverse events thought to
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be at least possibly related to imatinib. A 24‐month open‐label extension of this study dem‐
onstrated ongoing improvement in skin scores (p = 0.002) [48].
More recently, a phase II open‐label study recruited 30 patients with active SSc‐ILD, unre‐
sponsive to cyclophosphamide, and administered a lower dose of 200 mg daily of imatinib for
6 months [49]. Following an additional 6 months of follow‐up, a range of respiratory outcome
measures were assessed (with a ‘good response’ defined as an increase in FVC and/or DLco
of >15%, combined with a PaO2 of >90% of the initial value and stable/improved lung imaging).
Of the 26 subjects who completed the study, 4 subjects demonstrated a good response, 15
subjects had stable lung disease and 7 subjects had a worsening of their lung disease. Although
fewer patients reached the criteria of ‘good response’ than their goal of 30%, the authors
pointed out that their cohort of patients had advanced lung disease, unresponsive to conven‐
tional cyclophosphamide therapy. They suggested that a cohort of patients with earlier disease
might experience greater benefit from imatinib therapy. Importantly, the lower dose of imatinib
employed in this study was relatively well tolerated, with adverse events present in less than
20% of patients.
A second‐generation tyrosine kinase inhibitor, nilotinib, was recently tested in an open‐label
pilot study of 10 patients with early dcSSc [50]. Nilotinib has been shown to have a favourable
side‐effect profile relative to imatinib when used in chronic myeloid leukaemia patients [50].
In the seven patients who completed the study, significant reductions were seen in skin scores
after 6 months and 12 months of follow‐up (p = 0.02 and 0.01, respectively). Significant
improvements were also evident in the physician global assessment (p = 0.0013 at 12 months),
although no significant differences were evident in measures of lung function. Seventy‐one
adverse events, including two serious adverse events, were reported in the study, with
asymptomatic elevations in liver function tests and QTc prolongation being common adverse
events.
2.1.3. Other agents
Another study employed a different approach when searching for novel targeted therapies for
SSc [51]. Noting its proposed role as an autoantigen in SSc, the authors attempted to induce
immune tolerance to type I collagen by administering it orally to 168 patients with dcSSc in a
randomised, double‐blind, placebo‐controlled trial. In the primary efficacy outcome of mRSS,
no significant differences were evident between the treated and placebo cohorts at 15 months.
During subgroup analysis, the authors noted a significant reduction in mRSS in treated patients
with late‐phase disease (p = 0.0063), with the treatment effect first becoming apparent approx‐
imately 8 months after commencing treatment. Multiple adverse events were noted, although
this was common to both the treated and placebo arms of the study.
Although named after its pregnancy‐related functions, interest in recombinant human relaxin
as a potential therapy for SSc stems from its ability to inhibit fibroblast‐mediated collagen
production and enhance collagen breakdown. A phase II, randomised, controlled study of
recombinant human relaxin in patients with stable dcSSc demonstrated significant improve‐
ments in skin scores at 24 weeks, with evidence of benefit arising as early as 4 weeks into the
follow‐up period [52]. Following on from this study, Khanna et al. [53] performed a large phase
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III study of relaxin at two doses in patients with dcSSc. Reductions in skin scores were noted
in all groups, including placebo, with no significant differences between the study arms. No
significant differences were evident in functional outcome measures and FVC deteriorated in
patients receiving relaxin (p < 0.04). Furthermore, of the 36 subjects who dropped out of the
study prematurely, 14 were as a result of adverse events, most notably of the renal system.
2.2. Inflammation
2.2.1. TNFα inhibitors
Given the success of TNFα inhibitors in other autoimmune rheumatological conditions, several
studies have examined their use in SSc. Prior studies had shown that TNFα counters extrac‐
ellular matrix production by fibroblasts in vitro, leading to concerns that TNFα inhibitors might
potentiate fibrosis in SSc [54, 55]. This contrasted the results of several animal studies, where
TNFα abrogation resulted in reductions in fibrosis [54, 56, 57]. It has been proposed that the
effect of TNFα inhibition in SSc might vary depending on the stage of the disease. During the
early inflammation‐predominant phases of SSc, TNFα inhibitor‐mediated suppression of
inflammation may lead to a reduction in subsequent fibrosis, as seen in animal studies. This
is supported by the enhanced expression of TNFα in leucocytes from patients with early SSc
[58]. During the later fibrosis‐predominant stages of SSc, TNFα inhibitor‐mediated suppres‐
sion of inflammation is less likely to be of significance and may even be pro‐fibrotic in nature,
as suggested by in vitro studies [54, 59].
Lam et al. conducted a retrospective analysis of 18 patients with scleroderma‐associated joint
disease who had been treated with etanercept, a decoy receptor that binds to circulating
TNFα [60]. Concurrent treatment with other disease‐modifying agents or corticosteroids was
permitted in their analysis. Eighty‐three percent of patients demonstrated a positive response
to etanercept therapy, as determined by the treating physician on follow‐up review. Mean HAQ
scores and skin scores showed non‐significant trends towards improvement (p = 0.13 and 0.12,
respectively). Pulmonary function readings deteriorated during the course of etanercept
therapy, albeit to a small degree, in keeping with the gradual decline in lung function seen in
patients who did not receive etanercept therapy.
Infliximab, a chimaeric monoclonal antibody against TNFα, has also been tested in an open‐
label study of 16 patients with dcSSc [61]. In addition to a number of clinical outcome measures,
several histopathological and serum correlates of collagen synthesis were measured. No
significant difference was noted in skin scores at the 26‐week end point, although a non‐
significant trend towards a lower mRSS was evident at 22 weeks (p = 0.10). Significant reduc‐
tions were evident in the degree of type I collagen synthesis by dermal fibroblasts at 26 weeks
(p = 0.02) and in the serum levels of aminoterminal propeptide of type III collagen (p = 0.03).
Of the 127 adverse events that occurred during the course of the study, 19 adverse events were
thought to be attributable to infliximab, with half of the patients prematurely discontinuing
the therapy.
Following on from these studies, a multi‐centre, retrospective analysis of TNFα inhibitor use
in SSc was performed by the EULAR Scleroderma Trials and Research (EUSTAR) group [54].
Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis
http://dx.doi.org/10.5772/66642
109
Sixty‐five patients who had received an anti‐TNFα agent during the course of their treatment
(most commonly infliximab and etanercept) were identified. Of the 65 patients analysed, 48
had shown evidence of improvement, with the majority of benefit seen in patients with joint‐
related symptoms. Improvements in fibrosis were less convincing, with six patients experi‐
encing an improvement in fibrosis and seven patients experiencing a worsening of fibrosis.
Using the Delphi technique to reach an expert consensus, 50% of centres ultimately recom‐
mended against using TNFα inhibitors in SSc other than in the setting of clinical trials, 9% of
centres advised against their use entirely, and 38% of centres advocated consideration of
TNFα inhibitors in SSc‐associated joint disease.
2.2.2. Selective co‐stimulation modulators
Abatacept is a fusion protein comprising the extracellular domain of human cytotoxic T‐
lymphocyte‐associated antigen‐4 (CTLA‐4) and the modified Fc portion of human immuno‐
globulin G1 [62]. It is licensed as a treatment for moderate‐to‐severe rheumatoid arthritis that
has failed to respond to conventional immunosuppressant therapy, and has been shown to
have comparable efficacy to TNFα inhibitors [11, 63–65]. By binding to CD80/CD86 on the
surface of antigen‐presenting cells, abatacept inhibits the co‐stimulatory interactions required
for the activation of T‐cells. T‐cells have been strongly implicated in the pathogenesis of SSc
and, as such, a number of studies have investigated the role of abatacept as a treatment for SSc
[66, 67].
In a double‐blind, placebo‐controlled study, seven patients were randomised to receive
abatacept and compared to three control patients [67]. Although limited by the small number
of subjects, a trend towards improvement in absolute skin scores was noted with abatacept
therapy at the 24‐week end point (p = 0.0625). This improvement became statistically significant
when the differences in disease duration between the two cohorts were accounted for (p =
0.0114). Patients receiving abatacept therapy also noted greater improvements in HAQ and
visual analogue scores. Abatacept therapy was well tolerated, with no serious adverse events
noted during the course of the study.
The EUSTAR group's observational study of two separate biological therapies—abatacept and
tocilizumab (see below)—provides evidence to support abatacept's use in a cohort of patients
with SSc‐associated refractory arthritis [68]. Of the patients with joint disease receiving
abatacept therapy, 6/11 reached the EULAR‐specified criteria for a good response in their 28‐
joint count Disease Activity Score at 11 months. More impressive still was the 10/15 patients
who achieved a good response in their joint scores following tocilizumab therapy after 5
months of follow‐up. No benefit was seen in myopathic patients receiving abatacept therapy
or in skin or lung fibrosis with either abatacept or tocilizumab therapy.
2.2.3. IL‐2α inhibitors
Basiliximab, a chimaeric monoclonal antibody against CD25, disrupts T‐cell action via a
different mechanism to abatacept. The CD25 antigen corresponds to the alpha chain of the
interleukin‐2 (IL‐2α) receptor, a transmembrane protein expressed on the surface of activated
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T‐cells [69]. By competing with IL‐2 for access to its receptor, basiliximab disrupts the down‐
stream effects of activated T‐cells. Basiliximab has been utilised successfully as part of immu‐
nosuppressive regimens to prevent the acute rejection of transplanted organs [70]. The
promising results of a phase II study of basiliximab in patients with skin fibrosis resulting from
acute graft‐versus‐host disease also support its potential as a therapy for SSc [71].
Basiliximab was tested in an open‐label, prospective study of 10 patients with rapidly pro‐
gressive SSc [72]. As well as being relatively well tolerated, basiliximab therapy resulted in a
significant improvement in skin scores by week 68 of follow‐up (p = 0.015). A trend towards
an improvement in mean FVC was also noted by week 44 (p = 0.078). Given the small size and
open‐label nature of this study, further trials are necessary before definitive comments can be
made about basiliximab's efficacy in SSc. However, the results of this pilot study support the
beneficial response seen in a case study of a patient with recalcitrant SSc, who responded
favourably to basiliximab, in conjunction with cyclophosphamide [73].
2.2.4. IL‐6 inhibitors
Tocilizumab is a humanised monoclonal antibody targeting the interleukin‐6 (IL‐6) receptor.
As with abatacept and TNFα inhibitors, tocilizumab is an effective treatment for moderate‐to‐
severe rheumatoid arthritis which has failed to respond adequately to conventional disease‐
modifying agents. In addition to its pro‐inflammatory effects, IL‐6 has been shown to be pro‐
fibrotic, as well as an endothelial cell activator [74, 75]. IL‐6 levels are elevated in the serum of
patients with dcSSc and predict poorer long‐term clinical outcomes [75, 76].
Following on from the observational study of tocilizumab and abatacept in patients with SSc‐
associated joint disease (mentioned above), a case series published by Fernandes das Neves et
al. demonstrated evidence of clinical improvement in three treatment‐refractory SSc patients
treated with tocilizumab [68, 77]. More recently, the safety and efficacy of tocilizumab in SSc
was studied in a phase II, double‐blind, randomised, placebo‐controlled trial of 87 patients
with a disease duration of less than 5 years [78]. A trend towards improvement was evident
in the primary outcome (mean change in mRSS); however, this did not reach statistical
significance at 48 weeks (p = 0.0579). No significant difference was evident in clinical symptoms
or in global disease severity scores. However, significantly fewer patients in the tocilizumab
cohort experienced a decline in FVC at 48 weeks (p = 0.0373). A relatively large number of
patients in both cohorts experienced severe adverse events (33% treatment vs. 34% placebo),
with a greater number of serious infections noted in the tocilizumab cohort and one death as
a result of tocilizumab therapy. Further information about tocilizumab's efficacy and safety in
SSc will be provided by the ongoing phase III study [79].
2.2.5. B‐cell depletion
Rituximab is a chimaeric monoclonal antibody that targets the CD20 antigen, resulting in the
depletion of peripheral B‐cells. It has been shown to be highly effective in the treatment of
rheumatoid arthritis, where it is often used as a rescue therapy for patients with refractory
disease. Rituximab's clinical efficacy has to be weighed against the potential for serious side
Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis
http://dx.doi.org/10.5772/66642
111
effects, which include infusion reactions, predisposition to infection and hypogammaglobu‐
linaemia, and the serious but infrequent complication of progressive multifocal leukoence‐
phalopathy.
A body of evidence supporting the role of B‐cells in the pathogenesis of SSc has spurred interest
in rituximab as a therapy for SSc. Indeed, B‐cell depletion has been shown to suppress skin
fibrosis and autoantibody production in mouse models of SSc, when utilised in early stages of
the disease [80, 81]. An early, open‐label, pilot study of rituximab in 15 patients with dcSSc
produced disappointing results, however [82]. Although relatively safe and well tolerated,
rituximab therapy failed to produce a significant improvement in skin scores after 6 and 12
months of follow‐up (p = 0.82 and 0.83, respectively). This was despite demonstrable depletion
of B‐cells in the periphery and dermis. This pilot study has been followed by a number of
studies which support the role of rituximab therapy in SSc [83–90].
In a 1‐year prospective study by Daoussis et al., eight patients with SSc were randomised to
receive two cycles of rituximab therapy, in addition to standard treatment, and compared to
six patients who received standard treatment alone [87]. Relative to baseline, FVC improved
significantly with rituximab therapy at the 1‐year end point, with a median improvement of
10% (p = 0.0018). This was significantly improved relative to controls, where a median decline
in FVC of 5% was evident (p = 0.002). Significant improvements were also evident in DLco and
skin scores in the rituximab cohort (p = 0.017 and p < 0.001, respectively). An open‐label
extension of this study, whereby a further two cycles of rituximab therapy were administered,
demonstrated ongoing improvements in FVC, DLco and skin scores at 2 years [88].
A 2‐year, open‐label, prospective study by Smith et al. [89] provided further evidence of
rituximab's efficacy in SSc. Following two cycles of rituximab in eight patients with early dcSSc,
statistically significant reductions in skin scores, disease activity scores and biomarkers of
collagen deposition were evident by the 24‐month end point (p < 0.0001, p < 0.0001 and p =
0.009, respectively). The EUSTAR group employed a retrospective case‐control analysis to
collate evidence on rituximab use in SSc across a number of centres [81]. Sixty‐three patients
were identified who had received rituximab during the course of their treatment. Several
outcome measures were compared retrospectively to patients with SSc who had not received
rituximab therapy. In patients treated with rituximab, mean skin scores were found to be
significantly lower than baseline after a period of follow‐up (p = 0.0001). In the subset of patients
with severe dcSSc receiving rituximab, reductions in skin scores were significantly greater than
matched controls (p = 0.03). Furthermore, patients with SSc‐associated ILD experienced a
stabilisation in their FVC following rituximab therapy, relative to matched controls (p = 0.02).
More recently, an open‐label, prospective study of 30 SSc patients from three centres added
further weight to the evidence base supporting rituximab's use in SSc [90]. Patients received
four cycles of rituximab therapy over 18 months, followed by consideration for further cycles
by their treating physician. After 1 and 2 years of follow‐up, FVC had significantly improved
relative to baseline (p < 0.001 and p = 0.018, respectively), with the same being true of DLco at
2 years (P = 0.012). By 5 years, FVC was shown to have stabilised (p = 0.05). Skin scores also
improved significantly at all time points (P < 0.001). Again, rituximab was reported as being
relatively well tolerated in this study.
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Using a different approach, Schiopu et al. utilised a humanised anti‐CD19 monoclonal
antibody (MEDI‐551) to deplete B‐cells [91]. As noted by the authors, the CD19 antigen is
expressed on a wider range of B‐cell subsets than the CD20 antigen. In their study, 24 subjects
were randomised to receive a single dose of MEDI‐551 and compared to four subjects who
received placebo therapy. The primary aim of the study was to test MEDI‐551's safety and
tolerability in SSc subjects. An excess of adverse events was indeed noted in the treatment
cohort (95.8% of subjects) relative to the placebo cohort (75% of subjects), with the majority
being mild or moderate events. Of the serious adverse events, two were thought possibly to
have been a consequence of MEDI‐551 treatment. Given that a number of studies of rituximab
demonstrate the probable benefits of more prolonged B‐cell depletion in SSc, this 85‐day study
of MEDI‐551 was limited in its ability to discern clinical efficacy. A trend towards improvement
in skin scores with MEDI‐551 treatment was noted relative to placebo, although no clear
evidence of benefit was seen in pulmonary function tests. Further studies are needed to
determine its efficacy more conclusively.
2.2.6. Type I IFN receptor antagonists
Using another targeted approach to developing novel therapies for SSc, Goldberg et al. tested
MEDI‐546, a monoclonal antibody against the type I interferon (IFN) receptor, in patients with
SSc [92]. Case reports have documented incident systemic sclerosis arising in patients who had
previously received IFNα therapy for chronic viral hepatitis [93, 94]. An activated type I IFN
profile and gene signature are present in patients with SSc and administration of MEDI‐546
not only reduces serum levels of several IFN‐induced proteins but also suppresses levels of
markers of extracellular matrix turnover and TGF‐β signalling [95, 96].
In a study designed to test MEDI‐546's safety and tolerability in SSc, rather than its efficacy,
Goldberg et al. administered the treatment to 34 subjects and recorded a range of safety,
pharmacokinetic and immunogenicity outcomes after 12 weeks of follow‐up [92]. Of the 148
adverse events, four were recorded as serious adverse events, one of which was a new
diagnosis of chronic myelogenous leukaemia occurring after 10 months. Phase II, placebo‐
controlled studies are necessary before MEDI‐546's efficacy in SSc can be commented on.
Indeed, phase II studies of MEDI‐546 are already ongoing in systemic lupus erythematosus
(SLE).
2.3. Vascular
2.3.1. Endothelin receptor antagonists
The vasculopathy seen in SSc is characterised by endothelial cell damage and dysfunction and
fibrotic obliteration of the vasculature, with consequent ischaemia‐reperfusion injury [97].
This, in turn, stimulates the production of the potent vasoconstrictor, endothelin, which has
been strongly implicated as a mediator of vascular injury in SSc. The vascular manifestations
that result from these pathogenic processes include Raynaud's phenomenon (RP) and digital
ulceration, pulmonary arterial hypertension (PAH) and renal crises.
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One of few licensed targeted therapies for SSc is bosentan. Bosentan disrupts the endothelin‐
signalling axis by antagonising both of its receptors, endothelin‐A and endothelin‐B. Bosentan
has been shown in a large number of studies to be an effective treatment for PAH, including
SSc‐associated PAH (SSc‐PAH). Its use leads to improvements in symptoms, exercise capacity
and a range of haemodynamic values [98, 99]. Several studies have also investigated bosentan's
efficacy for the other vascular manifestations of SSc, most notably RP and digital ulceration,
details of which are given below.
The RAPIDS‐2 study was a large randomised, placebo‐controlled trial designed to evaluate
bosentan's efficacy in the treatment of SSc‐associated digital ulcers. One hundred and eighty‐
eight patients with SSc and active digital ulcers were recruited from a number of centres, of
which 98 were administered bosentan over the course of 20 weeks [100]. At the 24‐week end
point, a 30% reduction in the number of new digital ulcers was evident in the cohort receiving
bosentan (p = 0.04). No significant difference was evident in ulcer healing time, however. The
beneficial effects of bosentan on reducing digital ulcer formation are supported by two further
studies—a retrospective analysis of 67 patients and a 3‐year prospective, open‐label study
[101, 102]. Although generally well tolerated, all three studies demonstrated bosentan's well‐
documented side effect of inducing liver dysfunction. This is reversible in the vast majority of
cases, although close monitoring of liver function during therapy is essential. This is high‐
lighted by the results of a small study of bosentan in patients with SSc‐associated digital ulcers,
during which 50% of patients had to discontinue bosentan due to severe liver dysfunction [103].
It has been proposed that the differential effects of bosentan on digital ulcer formation and
healing might stem from various pro‐ and anti‐vasoconstrictive effects of the medication [104].
Ambrisentan also targets the endothelin axis but does so by selectively antagonising the
endothelin‐A receptor, as opposed to the dual‐receptor blockade mediated by bosentan. The
effects of ambrisentan on SSc‐associated digital ulcer number and healing were analysed in a
prospective, open‐label study of 20 patients [104]. A significant decrease in the number of
digital ulcers per patient was noted at 24 weeks relative to baseline (p < 0.004). The maximum
diameter of patients’ digital ulcers was also noted to decrease (p < 0.0001), and 88% of patients
who completed the study had full resolution of all their baseline digital ulcers. Importantly,
no study subjects developed deranged liver function tests during the course of this study.
The efficacy of ambrisentan in patients with SSc‐PAH has also been tested in a prospective,
open‐label study [105]. Twenty‐four patients with treatment‐naïve SSc‐PAH were adminis‐
tered dual therapy with ambrisentan and tadalafil, a phosphodiesterase type‐5 inhibitor, for
36 weeks. Following this course of treatment, significant reductions were noted in pulmonary
vascular resistance (p < 0.0001) and right ventricular mass (p < 0.05), as well as improvements
in 6‐min walk distances (p = 0.001) and other haemodynamic and structural outcome measures.
These results are supported by those of another study, in which 12 patients with SSc‐associated
exercise‐induced PAH experienced significant improvements in exercise‐pulmonary vascular
resistance and 6‐min walk distances following 24 weeks of treatment with ambrisentan (p =
0.004 and 0.003, respectively) [106].
Ambrisentan has also been shown to reduce the incidence of SSc‐associated Raynaud's
phenomenon (SSc‐RP) attacks, albeit it in a study of only six patients (p = 0.01) [107]. Bosentan's
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effect on SSc‐RP has been more extensively studied, with mixed results. In a retrospective
analysis of 14 patients, bosentan use was associated with a significant decrease in the number
and duration of RP attacks (p < 0.05) [97]. An open‐label prospective study of 15 patients with
lcSSc‐associated RP also demonstrated a significant reduction in the duration, frequency and
intensity of RP attacks with bosentan use (p < 0.05) [108]. These findings contrast the results of
a randomised, placebo‐controlled study involving 16 subjects with SSc‐RP (without pre‐
existing digital ulcers). Relative to placebo, no improvements in the duration, intensity or
frequency of RP attacks were seen with bosentan use, despite improvements in functional
scores.
In addition to endothelin's prominent role as a mediator of vascular injury in SSc, it has also
been implicated in promoting fibrosis. In vitro, endothelin stimulates production and deposi‐
tion of extracellular matrix by fibroblasts, as well as facilitating the pro‐fibrotic properties of
TGF‐β [97, 109, 110]. Endothelin levels are also elevated in the serum and bronchoalveolar
lavage fluid of patients with SSc‐ILD [111]. In light of endothelin's reported pro‐fibrotic roles,
the effects of bosentan on SSc‐associated skin and lung fibrosis have been tested in a number
of studies.
In a prospective, placebo‐controlled study of patients with SSc‐ILD, 77 patients were rando‐
mised to receive bosentan and their 6‐min walk distances and oxygen saturations compared
to 86 controls [112]. At 12 months, no significant difference was evident in walking distances
between the study cohorts (p = 0.404), with the same being true of pulmonary function test
results. Furuya et al. also examined bosentan's use in SSc‐ILD in a 24‐month open‐label trial
of 9 patients who were deemed ineligible for cyclophosphamide therapy [113]. Of the 7 patients
who completed the study, a trend towards improvement in FVC, DLco and total lung capacity
was noted. This contrasted the findings on high‐resolution computed tomography (CT) thorax
scans, which showed a gradual progression of the underlying fibrosis. Moreover, no benefit
on cumulative survival was evident when the subjects were compared to historical controls.
Bosentan's effect on skin fibrosis was evaluated in a retrospective, open‐label study of 14
patients who were receiving bosentan for SSc‐PAH [97]. As well as noting reductions in the
duration and number of RP attacks, significant reductions in skin scores were present in the
study cohort after 24 weeks of follow‐up (p < 0.01). The retrospective nature of this study and
the lack of control subjects both necessitate a degree of caution when interpreting these results,
particularly as spontaneous regression of skin disease is not uncommonly seen in SSc patients.
Indeed, Seibold et al.'s placebo‐controlled study of bosentan in SSc‐ILD (described above)
failed to show any significant treatment effect on skin thickness scores. This contrasts the
results of another, albeit much smaller, prospective study which did highlight a significant
improvement in mRSS with bosentan therapy (p < 0.001) [114]. Again, the lack of control
subjects in this study makes it difficult to separate bosentan's effects on skin scores from the
improvements sometimes seen in the natural progression of SSc.
Another endothelin‐receptor antagonist to have been studied in SSc is macitentan. Like
bosentan, macitentan acts to antagonise both of the endothelin receptors, albeit with a much
greater affinity for the endothelin‐A receptor. Macitentan's effects on SSc‐associated digital
ulcers were recently studied in two phase III placebo‐controlled trials with a total of 554 study
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subjects [115]. After 16 weeks of follow‐up, no significant treatment effect was evident in the
primary end point of cumulative number of new digital ulcers. The same was true of the
secondary end points of digital ulcer healing, total ulcer burden and hand function.
2.3.2. Other agents
Two other targeted vascular therapies worthy of mention are fasudil and ORM‐12741, both of
which have primary targets outside of the endothelin axis. Fasudil is a RhoA/Rho kinase
inhibitor that abrogates the α2C‐adrenoceptor‐mediated response to cold exposure, whereas
ORM‐12741 acts as a direct α2C‐adrenoceptor antagonist. When studied in patients with SSc‐
associated RP, neither agent enhanced recovery in blood flow nor skin temperature following
cold challenges [116, 117]. Although unsuccessful in their trials to date, fasudil and ORM‐12741
provide us with further examples of how research into the pathogenesis of SSc can be translated
into novel candidates for drug therapies.
3. Conclusion
In this chapter, we have reviewed a wide range of targeted therapies for SSc. Our systematic
literature search identified 69 clinical studies of targeted therapies with diverse modes of
action. This reflects the concerted efforts of clinicians and researchers trying to identify novel
therapies for this disabling condition.
Progress has already been made in improving the outlook for certain groups of patients with
SSc. Autologous haematopoietic stem cell transplantation, for example, has been shown to
benefit patients with early, aggressive dcSSc. Unfortunately, this benefit comes at the expense
of significant treatment‐related morbidity and mortality, thereby limiting the utility of this
treatment for the majority of patients with SSc.
The discovery of efficacious targeted therapies has the potential to transform the outlook for
patients with SSc, just as TNFα inhibitors have done in rheumatoid arthritis, psoriatic arthritis
and ankylosing spondylitis. In this regard, most progress has been made in developing
targeted therapies for the vascular manifestations of SSc. The endothelin‐receptor antagonists
bosentan and ambrisentan have been tested in more than 30 clinical studies involving patients
with SSc. As detailed above, many of these studies have demonstrated statistically significant
treatment effects on vascular manifestations such as PAH and digital ulcer formation. A phase
II study of zibotentan, a selective endothelin‐receptor A antagonist, is also currently underway
for patients with SSc‐associated renal dysfunction [118].
Improvements in our understanding of another of the central pillars of SSc pathogenesis –
fibrosis – have also been made. The studies of the anti‐TGF‐β antibodies, CAT‐192 and
fresolimumab, are excellent examples of how an understanding of the pathogenic processes
underlying SSc can be translated into targeted therapies. The improvements seen in skin
fibrosis scores following treatment with fresolimumab provide us with an exciting glimpse of
the potential benefits of targeted anti‐fibrotic therapies. This excitement is partly tempered by
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the large number of adverse events seen in this study; a clear reminder of the potential pitfalls
of disturbing physiological functions, such as fibrosis and healing.
Of the targeted anti‐inflammatory therapies, a great deal of optimism can be derived from the
studies of rituximab, a B‐cell‐depleting antibody with efficacy in a wide range of clinical
conditions. Of the 10 studies identified that assessed rituximab in SSc, 9 demonstrated
statistically significant treatment effects. Moreover, 6 of these studies revealed treatment
benefits in measures of both skin and lung fibrosis. Rituximab also provides us with an example
of how an existing targeted therapy can be adopted for use in SSc. Analysis of safety and
efficacy data from studies in other conditions can help tailor the design of studies of rituximab
in SSc and expedite the transition process.
As demonstrated in Table 1, a large number of the trials involving targeted therapies in SSc
have been small, open‐label studies. Their limited size and, in many cases, lack of control
subjects reduces the reliability of their outcome data. Large randomised, placebo‐controlled
studies are essential before definitive conclusions can be drawn about a particular treatment.
Performing such studies in SSc is challenging given the rarity of the condition and the
heterogeneity in its presentation and natural progression. Multi‐centre collaboration can help
to overcome these barriers by increasing the pool of subjects available for trials. Indeed, multi‐
centre randomised, controlled trials have already been performed for bosentan, macitentan,
tocilizumab, MEDI‐551, relaxin, oral type‐I collagen, CAT‐192 and imatinib mesylate. A
number of large randomised, placebo‐controlled trials are also ongoing for several of the
therapies covered in this chapter. Examples include the ASSET trial—a phase II study of
abatacept's efficacy in dcSSc—and the focuSSced trial—a phase III study of tocilizumab in SSc
[79, 119].
A better understanding of the pathogenic processes underlying SSc will help to reduce the
heterogeneity of study cohorts in trials of SSc. Stratification of patients into cohorts with
specific biochemical or clinical characteristics will permit tailoring of treatments to those
patients most likely to benefit. For example, an anti‐cytokine therapy might be offered to those
patients with a cytokine profile that suggests they are likely to benefit from such a therapy.
An improved understanding of the pathogenic processes underlying SSc will also increase
the number of available drug targets. Trials are currently underway for a number of agents
with novel mechanisms of action. The pan‐peroxisome proliferator‐activated receptor
(PPAR) agonist, IVA337, is currently being investigated in a phase II randomised, controlled
study of patients with dcSSc [120]. The anti‐fibrotic properties of PPAR agonists are support‐
ed by the results of a recent study in a mouse model of dermal fibrosis, in which IVA337
administration produced reductions in extracellular matrix deposition and several biomark‐
ers of inflammation and fibrosis [121]. Also promising is the ongoing phase III study of nin‐
tedanib in patients with SSc‐ILD [122]. Nintedanib is a tyrosine kinase inhibitor that targets
the receptors of vascular endothelial growth factor, fibroblast growth factor and PDGF. It
has been shown to retard the progression of idiopathic pulmonary fibrosis in phase III stud‐
ies and reduce fibrosis in multiple mouse models of SSc [123, 124]. Another candidate thera‐
py worthy of mention is riociguat, a soluble guanylate cyclase stimulator that possesses both
vasodilatory and anti‐fibrotic properties. Riociguat has been shown to improve exercise ca‐
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pacity and several other haemodynamic and functional outcomes in patients with sympto‐
matic PAH, and its effects on measures of skin and lung fibrosis are currently being assessed
in a phase II study of patients with dcSSc [125].
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